Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

ENLV Enlivex Therapeutics Ltd

1,36

-0,05 (-3,55%)

25 Jun 2024 - Fechado

Atrasado em 15 minutos

Yet Another Biotech Stock Has Found Success During Tuesday's Session

It appears to be the day for biotechs as yet another company in the space has caught our attention during Tuesday’s session. Earlier in the day, an Illinois-based biotech...

To read the full story on AllPennyStocks.com, click here.

Enlivex Therapeutics (NASDAQ:ENLV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Click aqui para mais gráficos Enlivex Therapeutics.

Enlivex Therapeutics (NASDAQ:ENLV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024

Click aqui para mais gráficos Enlivex Therapeutics.

Notícias Enlivex Therapeutics Ltd

Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Segunda, 24 de Junho de 2024 (2 dias atrás) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Quinta, 20 de Junho de 2024 (6 dias atrás) • Edgar (US Regulatory)

Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Quinta, 20 de Junho de 2024 (6 dias atrás) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 17 de Junho de 2024 (1 semana atrás) • Edgar (US Regulatory)

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
Segunda, 17 de Junho de 2024 (1 semana atrás) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Sexta, 14 de Junho de 2024 (2 semanas atrás) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 3 de Junho de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Segunda, 3 de Junho de 2024 (3 semanas atrás) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Quarta, 29 de Maio de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Quarta, 29 de Maio de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Quarta, 29 de Maio de 2024 (4 semanas atrás) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Terça, 28 de Maio de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Mais Notícias de Enlivex Therapeutics Ltd

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições